Report Contents
Market Overview
The global dried blood spot card market is currently generating approximately USD 0.45 Billion in revenue and is projected to reach about USD 0.56 Billion by 2032, reflecting a steady compound annual growth rate of 3.80% from 2026 to 2032. This expansion is driven by rising demand for decentralized diagnostics, large-scale newborn screening programs, and cost-optimized sample logistics that support high-throughput laboratory and biobank operations across both developed and emerging healthcare systems.
To capture this growth, companies must prioritize scalability of manufacturing and supply chains, localization of assay panels and regulatory strategies, and deep technological integration with laboratory information systems, automation, and digital tracking platforms. Converging trends in telehealth, home-based sampling, and precision medicine are broadening the clinical and research use cases for dried blood spot cards, shifting the market from a niche collection format to a strategic enabler of remote diagnostics and population health programs. This report positions itself as an essential strategic tool, providing forward-looking analysis of capital allocation, portfolio prioritization, partnership models, and disruptive innovations required to navigate the industry’s transformation and secure long-term competitive advantage.
Market Growth Timeline (USD Billion)
Source: Secondary Information and ReportMines Research Team - 2026
Market Segmentation
The Dried Blood Spot Card Market analysis has been structured and segmented according to type, application, geographic region and key competitors to provide a comprehensive view of the industry landscape.
Key Product Application Covered
Key Product Types Covered
Key Companies Covered
By Type
The Global Dried Blood Spot Card Market is primarily segmented into several key types, each designed to address specific operational demands and performance criteria.
-
Standard filter paper dried blood spot cards:
Standard filter paper dried blood spot cards represent the foundational segment of the market and currently account for a significant portion of routine neonatal screening, infectious disease surveillance, and population-level biomonitoring programs. Their established performance, low unit cost, and compatibility with existing laboratory protocols make them the default choice for many public health laboratories and reference centers. In a Global Dried Blood Spot Card Market valued at approximately USD 0.43 Billion in 2025, these cards hold a prominent share because they fit seamlessly into high-volume workflows without requiring specialized hardware.
The primary competitive advantage of standard filter paper cards lies in their cost-efficiency and proven analytical reliability across large test volumes. Many centralized laboratories report per-test consumable cost reductions in the range of 20–30 percent when switching from venous collection tubes to standard dried blood spot cards, driven by lower material use, reduced cold-chain storage, and lower transport weight. These cards also support throughput rates exceeding tens of thousands of samples per day in automated punching and elution systems, which is critical for national screening programs and epidemiological surveys.
The major growth catalyst for this segment is the continued expansion of government-sponsored newborn screening and infectious disease monitoring, particularly in emerging markets across Asia-Pacific, Latin America, and parts of Africa. As healthcare systems in these regions scale up screening coverage toward higher population penetration, demand for simple, low-cost, and robust collection media is expected to rise in step with the Global Dried Blood Spot Card Market CAGR of 3.80 percent through 2032. Additionally, donor-funded initiatives targeting HIV, hepatitis, and other communicable diseases continue to reinforce adoption of standard filter paper cards as a practical, field-ready solution.
-
Pre-printed and barcoded dried blood spot cards:
Pre-printed and barcoded dried blood spot cards occupy a rapidly professionalizing segment that focuses on sample identity integrity, chain-of-custody compliance, and automated data capture. These cards are increasingly selected by large hospital networks, centralized diagnostic chains, and biopharmaceutical sponsors conducting multicenter clinical trials. Their pre-printed identifiers and machine-readable barcodes reduce manual transcription, lower labeling error rates, and streamline integration with laboratory information systems and clinical data platforms.
The key competitive advantage of this type lies in traceability and workflow automation. Implementations in high-throughput clinical laboratories demonstrate sample mislabeling rate reductions of more than 80 percent when moving from handwritten labels to barcoded dried blood spot cards, directly improving data quality and reducing costly repeat testing. When combined with automated scanning, these cards can improve sample accessioning speed by 25–40 percent, which translates into faster turnaround times in time-sensitive applications such as therapeutic drug monitoring and clinical trial pharmacokinetic sampling.
Growth for pre-printed and barcoded dried blood spot cards is primarily fueled by digitalization of laboratory operations and tightening regulatory expectations around data integrity and audit trails. The expansion of decentralized and hybrid clinical trials, where thousands of participants mail in samples, is also accelerating demand because sponsors require robust subject tracking and chain-of-custody documentation. As more stakeholders standardize on end-to-end barcoded workflows to support scaling from hundreds to tens of thousands of subjects, this segment is expected to outpace the overall market growth rate and capture incremental value within the USD 0.56 Billion market anticipated by 2032.
-
Integrated collection device dried blood spot cards:
Integrated collection device dried blood spot cards combine the sampling mechanism and collection surface into a single unit, often incorporating capillary-based microcollection, metering, or safety features to control blood volume. This segment is strategically positioned for at-home sampling, remote patient monitoring, and primary care settings where phlebotomists and traditional venipuncture infrastructure are not readily available. Their user-friendly designs reduce technique variability and make self-collection feasible for patients in telehealth and chronic disease management programs.
The competitive advantage of integrated devices is their ability to deliver more consistent sample volumes and improved user safety, which leads to better analytical precision. Studies in patient self-collection settings have reported volume accuracy improvements of 15–25 percent compared with conventional fingerprick cards, with corresponding reductions in sample rejection rates due to under- or over-filled spots. Some integrated devices also incorporate automatic lancet retraction and splash protection, reducing accidental exposure incidents by a significant margin and supporting occupational safety standards.
Demand for this type is being driven heavily by the shift toward home-based diagnostics, remote clinical trial models, and value-based care pathways that depend on frequent, low-burden sampling. The rapid expansion of telemedicine infrastructures and remote therapeutic monitoring programs for conditions such as diabetes, autoimmune diseases, and rare metabolic disorders is creating new addressable volumes for integrated collection devices. As payers and providers seek to reduce in-clinic visits while maintaining high-frequency data collection, these devices are set to capture a disproportionate share of incremental market growth within the 2026–2032 forecast window.
-
Multi-spot dried blood spot cards:
Multi-spot dried blood spot cards feature multiple discrete collection zones, allowing different assays, time points, or replicate tests to be run from a single sampling event. This configuration is particularly important in multiplex screening, pharmacokinetic profiling, and biomarker discovery, where multiple analytes or confirmatory tests must be performed on the same patient sample. These cards are thus strongly positioned in advanced laboratory settings, contract research organizations, and specialized screening programs that prioritize analytical flexibility.
The primary competitive advantage of multi-spot cards is their ability to maximize information yield per collection, with some implementations enabling laboratories to conduct 3–5 distinct assays from one card without requiring additional patient blood draws. This can reduce patient burden and overall consumable use by an estimated 20–30 percent in complex testing panels, while maintaining robust quality control through built-in replicates. When integrated into high-throughput workflows, multi-spot formats also enable higher plate utilization rates and can improve assay throughput by more than 15 percent due to more efficient sample allocation.
Growth in this segment is being propelled by the increasing adoption of multiplex immunoassays, tandem mass spectrometry panels, and multi-omic profiling strategies that rely on parallel testing of numerous biomarkers. Pharmaceutical and biotech companies, in particular, are adopting multi-spot cards in early-phase and late-phase clinical studies to derive richer pharmacodynamic and safety datasets from limited patient samples. As precision medicine and companion diagnostics expand and require broader biomarker panels, the strategic importance of multi-spot dried blood spot cards is expected to rise, enabling this segment to capture high-value, specialized demand within the broader market trajectory.
-
Specialty treated dried blood spot cards:
Specialty treated dried blood spot cards are engineered with chemical coatings or surface modifications to stabilize labile analytes, inhibit enzymatic degradation, or inactivate pathogens. These cards are particularly significant for applications involving nucleic acids, certain hormones, volatile metabolites, or infectious agents that would otherwise degrade rapidly during transport or storage. They serve high-complexity laboratories, molecular diagnostics providers, and public health agencies that require reliable results from challenging or low-abundance biomarkers.
The key competitive advantage of specialty treated cards lies in enhanced analyte stability and biosafety, which directly improves result accuracy over extended transport times and ambient storage conditions. For example, treated cards can maintain acceptable recovery levels of specific nucleic acids or small molecules for up to 7–14 days at room temperature, compared with only a few days on untreated media, effectively extending the viable transport window by 50–100 percent. Some pathogen-inactivating cards also reduce viable organism load to below detectable levels, significantly decreasing biohazard risk while still preserving nucleic acid targets for downstream PCR or sequencing.
The main growth catalyst for this segment is the proliferation of molecular diagnostics and genomic epidemiology programs that depend on high-quality, stable samples collected in decentralized settings. Expanded use of dried blood spots for surveillance of emerging infectious diseases, pharmacogenomic testing, and specialized endocrine or metabolic profiling is driving laboratories to adopt treated cards to protect sample integrity. As more health systems in both developed and emerging regions implement molecular workflows outside tertiary centers, specialty treated dried blood spot cards are set to gain share in high-value, technically demanding applications aligned with the overall market expansion to 2032.
-
Dried blood spot sample collection kits:
Dried blood spot sample collection kits combine cards with lancets, alcohol swabs, instructions, packaging, and prepaid return materials into a single, patient-ready kit. This type plays a critical role in enabling direct-to-consumer testing, at-home sample collection for clinical laboratories, and remote enrollment in global clinical trials. By bundling all necessary components and standardized instructions, these kits simplify logistics, improve patient compliance, and expand the geographic reach of dried blood spot testing programs beyond traditional care settings.
The competitive advantage of complete collection kits is their impact on end-to-end operational efficiency and patient adherence. Programs using structured kits for home sampling have reported sample return rates exceeding 70–80 percent in certain remote patient monitoring and population screening initiatives, compared with substantially lower participation when relying on clinic-based collection alone. By standardizing materials and packaging, laboratories can also reduce inbound handling times and errors, frequently cutting manual intake time per kit by 20–30 percent while ensuring that specimens meet predefined quality criteria.
Growth in dried blood spot sample collection kits is being driven by the expansion of direct-to-consumer laboratory testing, remote clinical trial models, and chronic disease management programs that rely on postal or courier-based sample return. The increasing acceptance of mail-in testing for conditions such as dyslipidemia, thyroid disorders, and infectious disease screening is opening new consumer-centric channels and enabling laboratories to tap previously underserved populations. As the Global Dried Blood Spot Card Market increases from USD 0.43 Billion in 2025 to an estimated USD 0.56 Billion by 2032, integrated collection kits are expected to be a primary mechanism through which providers capture new volumes in home and community-based care pathways.
Market By Region
The global Dried Blood Spot Card market demonstrates distinct regional dynamics, with performance and growth potential varying significantly across the world's major economic zones.
The analysis will cover the following key regions: North America, Europe, Asia-Pacific, Japan, Korea, China, USA.
-
North America:
North America holds a strategically pivotal role in the global Dried Blood Spot Card market due to its advanced clinical diagnostics infrastructure, high adoption of newborn screening programs, and strong pharmaceutical and biotech R&D pipelines. The United States and Canada together account for a significant portion of global demand, driven by large-scale screening initiatives, decentralized sample collection in remote communities, and integration of dried blood spot testing into telehealth and home-based diagnostics workflows.
Within the global market that is projected to reach about 0.45 Billion by 2026 and 0.56 Billion by 2032 at a 3.80% CAGR, North America represents a mature, high-value revenue base with stable reimbursement frameworks. Untapped potential lies in expanding dried blood spot use for chronic disease management in rural and Indigenous populations, improving interoperability between labs and electronic health records, and harmonizing regulatory guidance for at-home sample kits, which still face barriers around patient education, sample integrity, and payer acceptance.
-
Europe:
Europe is a strategically important region for the Dried Blood Spot Card industry, supported by centralized laboratory networks, strong public health screening programs, and cross-border research collaborations. Countries such as Germany, the United Kingdom, France, Italy, and the Nordics act as primary drivers, especially in metabolic disorder screening, HIV and hepatitis surveillance, and long-term biobanking of dried samples for epidemiological studies.
Europe contributes a substantial share of global revenue, representing a relatively mature yet innovation-oriented market that reinforces global growth through method standardization and quality assurance frameworks. Significant untapped potential remains in Eastern and Southern Europe, where laboratory consolidation, harmonized procurement processes, and digital logistics could expand coverage. Key challenges include fragmented reimbursement policies between national health systems, varied data privacy regulations affecting sample tracking, and slow adoption of dried blood spot methods in specialty diagnostics where clinicians still prefer venous draws.
-
Asia-Pacific:
The broader Asia-Pacific region is emerging as a high-growth engine for the global Dried Blood Spot Card market, driven by large populations, expanding public health programs, and growing pharmaceutical outsourcing. Countries such as India, Australia, Singapore, and several Southeast Asian economies are increasingly using dried blood spot cards for neonatal screening, infectious disease monitoring, and pharmacokinetic studies associated with clinical trials conducted for global sponsors.
Although Asia-Pacific currently represents a smaller share of the approximately 0.43 Billion market size in 2025 compared with North America and Europe, its higher growth trajectory significantly contributes to the global 3.80% CAGR. Untapped opportunities are concentrated in rural healthcare outreach, community-based HIV and hepatitis testing, and remote therapeutic drug monitoring for tuberculosis and antiretroviral therapies. Challenges include inconsistent cold-chain and logistics practices, variable regulatory frameworks for sample export, and limited awareness among primary-care providers about the accuracy and reliability of dried blood spot methodologies.
-
Japan:
Japan represents a distinct and strategically relevant submarket within Asia for dried blood spot cards, characterized by advanced hospital systems, strong regulatory oversight, and high expectations for analytical precision. The country has well-established newborn screening programs and a growing emphasis on population-level genomic and metabolic studies that increasingly integrate dried blood spot sample collection to support long-term cohort research.
Japan contributes a notable share of regional Asia-Pacific revenue and serves as a reference market for high-quality manufacturing standards and method validation, reinforcing global confidence in dried blood spot technology. Untapped potential exists in expanding use for therapeutic drug monitoring in oncology and rare disease management, as well as in home-based sampling for elderly and home-care patients. Key barriers include conservative clinical practice, lengthy reimbursement assessments for novel uses, and the need for more localized evidence demonstrating equivalence to traditional venous sampling in complex assays.
-
Korea:
Korea is an increasingly influential participant in the Dried Blood Spot Card industry, supported by its strong healthcare IT infrastructure, high smartphone penetration, and rapidly advancing biotech sector. The country’s centralized public health system and robust reference laboratories enable efficient deployment of dried blood spot workflows for neonatal screening, infectious disease surveillance, and clinical trial sampling for domestic and multinational sponsors.
Korea’s share of the global market is smaller in absolute terms but growing faster than the global 3.80% CAGR, positioning it as a dynamic regional growth contributor. Significant opportunities lie in linking dried blood spot collection with digital health platforms for remote monitoring of metabolic and chronic conditions, especially in aging populations. Key challenges involve aligning national regulatory guidance with international bioanalytical standards, scaling manufacturing of high-specification cards locally, and encouraging broader adoption among clinicians who remain accustomed to hospital-based phlebotomy practices.
-
China:
China is one of the most strategically important high-growth markets for dried blood spot cards, given its large population, expanding basic medical insurance coverage, and rapidly modernizing laboratory infrastructure. Major urban centers such as Beijing, Shanghai, and Guangzhou act as hubs for newborn screening expansion, infectious disease testing, and bioanalytical services that incorporate dried blood spot methods to manage high sample volumes and geographically dispersed populations.
China’s market share within the global Dried Blood Spot Card sector is increasing steadily and is expected to contribute materially to the forecast rise from 0.43 Billion in 2025 to 0.56 Billion by 2032. Untapped potential is concentrated in county-level and rural healthcare systems, where dried blood spot sampling can overcome scarcity of skilled phlebotomists and limited cold-chain infrastructure. Challenges include uneven laboratory quality standards between provinces, complex and evolving regulatory pathways for in vitro diagnostics, and procurement policies that can favor low-cost options over premium, high-performance cards required for sensitive assays.
-
USA:
The USA forms the single largest national market within the global Dried Blood Spot Card industry and serves as a primary reference point for innovation, regulatory benchmarks, and large-scale screening program design. The country’s established newborn screening mandates, extensive clinical trial activity, and rapid growth in mail-in laboratory testing for wellness and chronic disease monitoring drive recurrent demand for high-quality dried blood spot cards.
The USA accounts for a substantial portion of North American revenue and is central to the global market’s progression toward 0.45 Billion in 2026, providing both a stable revenue core and a testing ground for new decentralized diagnostic models. Untapped opportunities include broader payer-backed adoption of home-based dried blood spot kits for diabetes, lipid disorders, and therapeutic drug monitoring, especially in underserved rural and inner-city communities. Key constraints involve reimbursement complexity, differing state-level laboratory regulations, and ongoing requirements to educate clinicians and consumers about correct sampling technique to ensure consistent analytical performance.
Market By Company
The Dried Blood Spot Card market is characterized by intense competition, with a mix of established leaders and innovative challengers driving technological and strategic evolution.
-
PerkinElmer Inc.:
PerkinElmer Inc. plays a pivotal role in the dried blood spot card market, particularly through its deep integration in newborn screening, infectious disease monitoring, and public health laboratory workflows. The company’s portfolio spans filter paper card systems, automated punchers, and analytical instruments, which allows it to offer end-to-end DBS solutions rather than standalone consumables. This systems-based approach embeds PerkinElmer in national screening programs and hospital networks, creating high switching costs for laboratories and healthcare providers.
In 2025, PerkinElmer’s dried blood spot card business is estimated to generate revenue of approximately USD 0.08 Billion, corresponding to a market share of about 18.50% of the global dried blood spot card market. These figures indicate that PerkinElmer is one of the largest participants in the segment, with a leadership position in high-throughput clinical screening applications. The company’s scale enables it to negotiate favorable supply contracts with public health agencies and to invest consistently in card chemistry, workflow automation, and laboratory informatics.
PerkinElmer’s competitive differentiation stems from its ability to link dried blood spot cards with validated immunoassay platforms, tandem mass spectrometry systems, and integrated data analysis software. This combination provides laboratories with proven, regulatory-compliant workflows from sample collection to result reporting. Strategically, PerkinElmer leverages long-term framework agreements with governments and reference laboratories, as well as training and technical service networks in North America, Europe, and Asia-Pacific, to defend its installed base and capture incremental demand from expanded neonatal and metabolic screening panels.
-
QIAGEN N.V.:
QIAGEN N.V. is a critical player in the dried blood spot card market due to its strong positioning in sample preparation, molecular diagnostics, and nucleic acid stabilization technologies. While QIAGEN is best known for its DNA and RNA extraction kits, it has increasingly optimized its chemistries and protocols for dried blood spot matrices, enabling reliable molecular testing from minimal blood volumes. This capability is important for virology, genomics, and pharmacokinetic monitoring programs that rely on DBS sampling.
For 2025, QIAGEN’s revenue from products and solutions tied directly to dried blood spot card workflows is estimated at around USD 0.04 Billion, with a corresponding market share near 9.50%. These levels place QIAGEN among the leading technology providers in molecular DBS applications, although it competes more through added-value reagents and extraction systems than through high-volume card sales. Its market share reflects strong uptake of DBS-compatible assays in HIV viral load monitoring, hepatitis testing, and research-use-only genotyping.
QIAGEN’s strategic advantage lies in its integration of dried blood spot sample preparation with standardized assay menus on platforms used widely in diagnostic and research laboratories. By publishing validated protocols for DBS extraction on existing instruments, QIAGEN lowers adoption barriers and encourages laboratories to expand into remote sample collection using existing infrastructure. Its partnerships with global health initiatives and non-governmental organizations increase the relevance of DBS-based screening in low-resource settings, where cold-chain logistics for venous blood samples remain a major constraint.
-
Shimadzu Corporation:
Shimadzu Corporation contributes to the dried blood spot card ecosystem primarily through its mass spectrometry and analytical instrumentation, which are widely deployed for quantitative analysis of analytes collected on DBS cards. The company supports clinical toxicology, therapeutic drug monitoring, and metabolomics workflows that depend on accurate and sensitive detection from dried blood matrices. This makes Shimadzu a key enabler of high-value DBS applications rather than a dominant supplier of the physical cards themselves.
In 2025, Shimadzu’s revenue directly attributable to dried blood spot card–related workflows is estimated at approximately USD 0.03 Billion, translating into a market share of about 7.00% in the broader DBS card market when considering instrument-linked card demand. These figures signal a solid, technologically influential position in the higher-end analytical segment, supporting laboratories that require robust quantification from DBS samples. While Shimadzu’s volume in pure card consumables is modest, its installed base of LC-MS/MS and other analytical platforms drives recurring use of DBS cards purchased from partner manufacturers.
Shimadzu differentiates itself through high-sensitivity, high-throughput mass spectrometers optimized for low-volume samples and complex matrices. By providing validated methods and application notes tailored to dried blood spot analysis, the company helps laboratories shorten method development time and improve data reliability. Strategic collaborations with clinical reference laboratories, pharmaceutical companies, and academic centers further entrench Shimadzu in specialized DBS workflows such as newborn screening panels, biomarker quantification, and bioequivalence studies in clinical pharmacology.
-
HemaXis SA:
HemaXis SA is a specialized innovator in capillary blood microsampling and dried blood spot solutions, focusing on user-friendly collection devices that enhance sample quality and patient experience. Its products are designed to standardize the blood volume applied to DBS cards and to minimize pre-analytical variability, which is a critical barrier to broader clinical adoption. HemaXis targets decentralized testing, home-based sampling, and remote clinical trials where logistical simplicity and sample integrity are essential.
For 2025, HemaXis SA is estimated to generate around USD 0.01 Billion in revenue from dried blood spot card and microsampling solutions, corresponding to an approximate market share of 2.50%. While this scale is smaller than that of diversified diagnostics conglomerates, it positions HemaXis firmly in the high-growth niche of patient-centric sampling for telemedicine and decentralized clinical research. Its market share reflects growing adoption among contract research organizations and digital health companies seeking to reduce patient site visits.
HemaXis’s core capabilities include device engineering that controls blood volume and uniform card saturation, along with ergonomic designs that improve patient compliance. The company differentiates itself by combining card technology with user instructions, packaging, and logistics workflows tailored to direct-to-patient shipments. Strategically, HemaXis collaborates with assay developers and central laboratories to validate DBS-based protocols, allowing pharmaceutical sponsors and diagnostics providers to integrate its devices into hybrid and fully remote study designs.
-
Eastern Business Forms Inc.:
Eastern Business Forms Inc. occupies an important position as a specialized manufacturer of dried blood spot cards and related filter paper products. Its expertise in precision cutting, coating, and quality control of cellulose-based substrates underpins reliable sample absorption, homogeneity, and long-term stability. The company serves diagnostic kit manufacturers, hospitals, and public health programs that require consistent, validated DBS card supply at scale.
In 2025, Eastern Business Forms’ dried blood spot card operations are estimated to achieve revenue of about USD 0.02 Billion, yielding a market share in the vicinity of 4.50%. This performance highlights its role as a significant mid-tier supplier in the global DBS card landscape, especially for neonatal screening and epidemiological surveillance programs. Its share reflects strong demand from institutions that prioritize cost-effective yet rigorously standardized consumables.
The company’s strategic strength lies in its manufacturing reliability, customization capabilities, and adherence to international standards for diagnostic-grade filter paper. Eastern Business Forms often provides private-label or co-branded cards to larger diagnostics companies, embedding itself in broader product portfolios without always being visible to end users. This contract manufacturing and supply-chain-focused strategy allows the company to maintain high utilization of its production capacity while avoiding the cost of building global sales and marketing infrastructures comparable to larger multinationals.
-
Danaher Corporation:
Danaher Corporation participates in the dried blood spot card market through several of its operating companies, which collectively address sample collection, analytical instrumentation, and clinical diagnostics workflows. Its presence is particularly pronounced in immunoassays, mass spectrometry, and automated laboratory systems that routinely process DBS samples. Danaher’s portfolio approach makes it an influential ecosystem player, even when DBS cards themselves represent a modest portion of its overall revenue.
For 2025, Danaher’s revenue linked directly to dried blood spot card usage, including associated consumables and platform solutions, is estimated at around USD 0.05 Billion, equating to an approximate market share of 11.50%. These figures underscore the company’s strong competitive position, particularly in laboratories that integrate DBS sampling into high-throughput analytical workflows. Danaher’s scale and cross-portfolio synergies allow it to influence procurement decisions and laboratory standardization initiatives in ways that smaller competitors cannot easily replicate.
Danaher’s strategic advantages stem from its continuous improvement culture, disciplined acquisition strategy, and ability to integrate newly acquired technologies into cohesive diagnostic workflows. By offering DBS-compatible analyzers, reagents, and informatics solutions, Danaher enables customers to expand from conventional venous sampling to dried blood spot workflows without overhauling their infrastructure. Partnerships with biopharmaceutical companies for therapeutic drug monitoring and bioanalysis further reinforce Danaher’s role in the evolution of evidence-based precision medicine using capillary blood sampling.
-
Ahlstrom Oyj:
Ahlstrom Oyj is a foundational supplier in the dried blood spot card market through its advanced fiber-based materials used as the core substrate for many DBS cards. The company’s expertise in specialty papers, absorbent materials, and functional coatings supports consistent blood absorption, analyte retention, and dimensional stability. Many diagnostics companies rely on Ahlstrom’s filter papers as a critical raw material for their finished DBS cards.
In 2025, Ahlstrom’s revenue directly related to dried blood spot card substrates is estimated at approximately USD 0.02 Billion, with a market share of around 4.00% when considering its role in the value chain. While Ahlstrom may not always appear as the brand on the final card product, its share reflects widespread use of its specialty papers across multiple card manufacturers. The company’s output underpins a significant portion of the global installed base of DBS cards used in clinical and research settings.
Ahlstrom’s competitive edge lies in its materials science capabilities and its ability to engineer papers with controlled porosity, thickness, and chemical background that are suitable for a broad set of assays. By working closely with diagnostics firms on co-development projects, Ahlstrom ensures that its substrates meet stringent regulatory and performance requirements. This upstream position in the supply chain allows the company to influence technical standards and to capture demand growth as dried blood spot sampling expands into new therapeutic areas and geographies.
-
Cardinal Health Inc.:
Cardinal Health Inc. plays a distribution-centric and logistics-oriented role in the dried blood spot card market. While it is not primarily a manufacturer of DBS cards, it serves as a key channel partner that ensures reliable availability of dried blood spot cards, lancets, and associated supplies to hospitals, clinics, and reference laboratories. Cardinal’s extensive distribution network enables broad penetration of DBS products in both mature and emerging healthcare systems.
For 2025, Cardinal Health’s revenue attributable to the sale and distribution of dried blood spot cards and related consumables is estimated at about USD 0.02 Billion, corresponding to a market share of around 4.00%. These figures reflect its importance as a volume mover rather than as an innovator in card design or chemistry. Cardinal’s participation supports steady, predictable demand for DBS card manufacturers that rely on its logistics infrastructure to reach diverse customer segments.
Cardinal Health’s strategic advantage is its scale in medical-surgical distribution, integrated inventory management services, and ability to bundle DBS cards with broader laboratory and point-of-care product portfolios. By offering data-driven demand forecasting and automated replenishment services, the company helps clinical customers avoid stock-outs and maintain continuity in newborn screening and chronic disease monitoring programs. Its reach across the United States and into select international markets makes Cardinal an essential partner for DBS suppliers seeking rapid market access without building their own logistics networks.
-
Neoteryx LLC:
Neoteryx LLC is a leading specialist in volumetric microsampling, offering devices and cards that enable precise collection of fixed blood volumes for dried blood analysis. Its Mitra-based technologies and related products are widely used in remote patient monitoring, decentralized clinical trials, and toxicology testing, where accurate, volume-controlled sampling is more critical than traditional spot saturation. Neoteryx positions itself as a technology-driven alternative to conventional DBS cards.
In 2025, Neoteryx’s revenue from volumetric microsampling devices and compatible cards used in dried blood analysis is estimated at approximately USD 0.03 Billion, supporting a market share near 7.50% within the broader dried blood spot card and microsampling segment. These figures demonstrate its strong foothold among pharmaceutical sponsors, contract research organizations, and specialty laboratories seeking higher analytical precision from capillary blood samples. Neoteryx’s share highlights the growing shift from traditional DBS cards to volumetric solutions in applications with stringent regulatory and bioanalytical requirements.
Neoteryx differentiates itself through proprietary absorptive tips, standardized collection volumes, and well-characterized hematocrit performance, all of which reduce variability and facilitate regulatory acceptance in pharmacokinetic and toxicokinetic studies. The company builds strategic value by collaborating with global biopharmaceutical companies to validate microsampling methods and by offering training, protocols, and study support for remote sampling implementations. These capabilities position Neoteryx as a key catalyst in the modernization of clinical trial and therapeutic monitoring workflows using dried blood methodologies.
-
Spot On Sciences Inc.:
Spot On Sciences Inc. is an innovation-focused company dedicated to simplifying dried blood collection and improving sample stability in non-clinical settings. Its devices are designed for intuitive self-sampling, enabling patients to collect high-quality dried blood specimens at home or in community settings without specialized training. This focus directly supports the expansion of telehealth, home diagnostics, and epidemiological surveillance that rely on distributed sampling.
For 2025, Spot On Sciences is estimated to achieve revenue of around USD 0.01 Billion from dried blood spot card devices and kits, with a market share of approximately 2.00%. Although modest in absolute size, this share underscores its influence in early-adopter segments such as digital health platforms and niche research programs. The company’s growth trajectory is closely linked to the acceleration of home-based testing models and the convergence of DBS sampling with app-based engagement and tracking tools.
Spot On Sciences’ competitive differentiation lies in user-centric design, integrated packaging for mail-back logistics, and emphasis on real-world usability testing. By working with clinical laboratories to validate home-collected samples for specific analytes, the company builds confidence in the reliability of patient-driven sampling. Strategic collaborations with telemedicine providers and health systems exploring hybrid care pathways position Spot On Sciences as an important enabler of decentralized diagnostics and population-level screening initiatives.
-
Bio-Rad Laboratories Inc.:
Bio-Rad Laboratories Inc. holds a significant niche in the dried blood spot card market through its quality control materials, diagnostic reagents, and immunoassay solutions that are adapted for DBS matrices. Clinical laboratories use Bio-Rad’s controls and calibration materials to verify the accuracy of assays run on dried blood samples, particularly in newborn screening, endocrinology, and infectious disease testing. This role makes Bio-Rad a quality assurance backbone in DBS-based diagnostic workflows.
In 2025, Bio-Rad’s revenue associated with dried blood spot card–related products, including controls and reagents, is estimated at approximately USD 0.03 Billion, representing a market share of about 7.00%. These figures indicate a robust presence in laboratories that rely on standardized, traceable quality control materials to ensure regulatory compliance and analytical reliability. Bio-Rad’s position reinforces confidence in DBS-based testing, which is crucial for sustained adoption by public health programs and clinical laboratories.
Bio-Rad’s strategic advantages include its long-standing relationships with clinical laboratories, extensive portfolio of controls that mimic real patient samples, and strong technical support infrastructure. By tailoring its quality control offerings to dried blood cards and providing guidance on assay performance verification, Bio-Rad helps laboratories integrate DBS testing into routine workflows with minimal disruption. This emphasis on quality and regulatory readiness differentiates the company from purely consumables-focused competitors and secures recurring revenue based on ongoing proficiency requirements.
-
Roche Diagnostics:
Roche Diagnostics exerts significant influence in the dried blood spot card market through its broad diagnostic platforms and menu of assays that can be adapted to DBS samples for certain applications. While Roche is best known for its high-throughput analyzers and centralized laboratory systems, it increasingly supports alternative sampling strategies, including dried blood, to extend testing access and facilitate patient-centric care models. This positions Roche as a strategic partner for health systems exploring hybrid sampling modalities.
For 2025, Roche Diagnostics’ revenue linked to dried blood spot card–enabled testing is estimated at around USD 0.04 Billion, reflecting a market share of approximately 9.00%. These figures highlight Roche’s role as a major technology provider whose platforms drive demand for DBS cards, even if the company does not focus on manufacturing the cards themselves. Its share underscores strong participation in infectious disease monitoring, metabolic screening, and chronic disease marker testing that can leverage DBS specimens in selected contexts.
Roche’s competitive edge stems from its comprehensive diagnostic ecosystem, which combines analyzers, reagents, digital solutions, and clinical decision support tools. By collaborating with laboratories to validate specific assays for dried blood spot samples and by integrating DBS workflows into its connectivity and data management platforms, Roche lowers barriers to adoption. The company’s global reach, robust clinical trial support, and reputation for assay robustness make it a preferred partner for large-scale screening programs that aim to incorporate DBS sampling alongside traditional venous draws.
-
Tecan Group Ltd.:
Tecan Group Ltd. is a key automation provider to laboratories that process dried blood spot cards at medium to high throughput. Its liquid handling platforms, robotic punchers, and integrated sample preparation systems streamline the cutting, elution, and transfer of dried blood punches into assay-ready formats. This automation capability is critical for scaling DBS-based programs in newborn screening, therapeutic drug monitoring, and research biobanking.
In 2025, Tecan’s revenue attributable to dried blood spot card automation solutions and related integrations is estimated at approximately USD 0.02 Billion, which corresponds to a market share of around 4.50% in the DBS card value chain. This share underscores Tecan’s importance in enabling throughput and consistency, particularly in laboratories that must handle tens of thousands of DBS samples per year. Its solutions directly influence the operational efficiency and cost-per-test economics of DBS programs.
Tecan differentiates itself through modular, configurable platforms that can be tailored to laboratory space, throughput, and workflow requirements. By partnering with diagnostics companies and public health laboratories to design standardized DBS processing lines, Tecan helps customers reduce manual handling errors and enhance traceability. Its strategic focus on open-platform automation allows laboratories to adapt Tecan systems to both commercial and laboratory-developed tests, creating flexibility as DBS applications evolve and expand.
-
Eurofins Scientific:
Eurofins Scientific is a major contract laboratory and analytical service provider that uses dried blood spot cards extensively in its testing services. It offers DBS-based analyses in toxicology, pharmacokinetics, nutritional assessment, and environmental exposure monitoring, among other areas. By integrating dried blood spot sampling into its global laboratory network, Eurofins provides pharmaceutical sponsors, researchers, and healthcare organizations with a scalable service model for decentralized sample collection.
For 2025, Eurofins’ revenue derived from services using dried blood spot cards is estimated at around USD 0.03 Billion, equating to a market share of approximately 7.00% when measured by DBS-related value creation. These figures demonstrate the company’s role as a high-impact downstream user that drives recurring demand for DBS cards and associated logistics services. Eurofins’ adoption of DBS methods helps validate the technology in regulated environments and provides real-world evidence of feasibility at commercial scale.
Eurofins’ strategic strengths include its global laboratory footprint, broad menu of DBS-validated assays, and experience navigating regulatory and quality requirements across multiple jurisdictions. The company works closely with biopharmaceutical firms to design DBS-based sampling strategies for clinical trials, often combining traditional venous sampling with capillary-based approaches to optimize patient convenience and data quality. This capability positions Eurofins as a strategic partner for organizations seeking to operationalize dried blood spot methods without building in-house testing capacity.
-
Laboratory Corporation of America Holdings:
Laboratory Corporation of America Holdings, commonly known as Labcorp, is one of the largest clinical laboratory networks globally and an influential user and promoter of dried blood spot card testing. Labcorp incorporates DBS sampling into selected screening, monitoring, and clinical trial services, enabling broader geographic reach and enhanced patient convenience. Its adoption decisions strongly influence healthcare providers and payers evaluating the practicality of DBS-based diagnostics.
In 2025, Labcorp’s revenue connected to services utilizing dried blood spot cards is estimated at approximately USD 0.04 Billion, supporting a market share in the vicinity of 9.00%. These figures underscore the company’s significant role in converting theoretical DBS advantages into routine clinical practice and commercial service offerings. Labcorp’s scale enables it to pilot and then roll out DBS-based tests across wide patient populations, thereby creating sustained demand for card manufacturers and logistics providers.
Labcorp’s competitive differentiation arises from its comprehensive test menu, payer relationships, and ability to integrate dried blood spot sampling into established phlebotomy, home collection, and digital ordering channels. The company collaborates with diagnostics manufacturers, digital health firms, and pharmaceutical sponsors to validate DBS-based protocols and to design patient-friendly collection kits. By combining analytical expertise with robust sample logistics and data reporting capabilities, Labcorp acts as a key accelerator for the mainstream adoption of dried blood spot card testing in both clinical diagnostics and clinical research.
Key Companies Covered
PerkinElmer Inc.
QIAGEN N.V.
Shimadzu Corporation
HemaXis SA
Eastern Business Forms Inc.
Danaher Corporation
Ahlstrom Oyj
Cardinal Health Inc.
Neoteryx LLC
Spot On Sciences Inc.
Bio-Rad Laboratories Inc.
Roche Diagnostics
Tecan Group Ltd.
Eurofins Scientific
Laboratory Corporation of America Holdings
Market By Application
The Global Dried Blood Spot Card Market is segmented by several key applications, each delivering distinct operational outcomes for specific industries.
-
Newborn screening:
Newborn screening is the most entrenched application of dried blood spot cards, with national programs in many countries screening nearly all live births for metabolic, endocrine, and genetic disorders. The core business objective is to detect treatable conditions within days of birth, preventing long-term disability and reducing lifetime healthcare costs. Dried blood spot cards enable centralized laboratories to process hundreds of thousands of specimens annually, supporting the broad coverage required for population-wide screening and anchoring a significant share of the overall market revenue.
The use of dried blood spot cards in newborn screening delivers unique operational outcomes compared with venous sampling, primarily through streamlined logistics and high-throughput processing. Centralized screening laboratories frequently handle more than 5,000 cards per day, with automated punching and tandem mass spectrometry workflows delivering turnaround times of under 48 hours for a majority of specimens. Cost-effectiveness analyses often show that dried blood spot-based newborn screening yields attractive payback periods, because early diagnosis can avoid decades of expensive care for untreated conditions, generating savings that can exceed screening program costs by several multiples.
Growth in this application is driven by regulatory mandates that expand newborn screening panels and by policy decisions in emerging economies to roll out nationwide programs. Many jurisdictions are adding new conditions to their mandated panels, which increases test menu complexity while keeping the same dried blood spot collection platform. At the same time, international funding agencies and health ministries are investing in basic screening infrastructure, particularly in regions where coverage rates are still catching up to high-income markets, sustaining long-term demand for cards and associated consumables.
-
Infectious disease testing:
Infectious disease testing using dried blood spot cards targets conditions such as HIV, hepatitis, and other blood-borne or vaccine-preventable infections, with a primary business objective of expanding diagnostic reach to remote and underserved populations. Programs leveraging dried blood spots can collect specimens in peripheral clinics or community settings and ship them to central reference laboratories without cold-chain logistics. This enables large-scale screening and monitoring activities that would be prohibitively expensive or operationally complex with plasma or serum samples.
The operational advantage of dried blood spot-based infectious disease testing lies in the significant reduction in transport and storage costs and in the ability to maintain sample integrity over long distances. Public health programs frequently report logistics cost reductions in the range of 30–50 percent when shifting from refrigerated tube transport to ambient dried blood spot shipments, particularly in regions with limited infrastructure. At the same time, centralized laboratories can batch and process thousands of cards per week using standardized ELISA or nucleic acid testing workflows, enhancing throughput without proportional increases in staffing.
The main catalyst for adoption and expansion in this application is the global emphasis on achieving diagnostic coverage targets and monitoring treatment outcomes for major infectious diseases. Donor-funded initiatives and national strategies aimed at eliminating hepatitis C, controlling HIV, and tracking vaccine-preventable diseases are explicitly prioritizing field-friendly sampling solutions. As molecular assays become more tolerant of dried blood spot matrices and validation data accumulate, health systems are increasingly incorporating these cards into guidelines and protocols, reinforcing demand in line with the Global Dried Blood Spot Card Market’s steady CAGR of 3.80 percent.
-
Therapeutic drug monitoring:
Therapeutic drug monitoring applications focus on measuring drug levels for conditions such as HIV, epilepsy, oncology, and autoimmune diseases, with the business objective of optimizing dosing and minimizing adverse events. Dried blood spot cards allow patients to provide small-volume samples at home or in outpatient settings, which are then analyzed by specialized laboratories. This reduces the need for in-clinic venipuncture and enables more frequent monitoring, which is especially valuable for drugs with narrow therapeutic windows.
Operationally, dried blood spot-based therapeutic drug monitoring can increase testing frequency while holding or even reducing overall care delivery costs. Clinical programs that transition stable patients to remote dried blood spot sampling often report reduced clinic visit frequency by 20–40 percent, freeing capacity for more complex cases while maintaining or improving clinical outcomes. Laboratories benefit from the ability to batch samples and run high-throughput LC-MS/MS assays, which supports efficient utilization of analytical platforms and contributes to faster, standardized turnaround times.
The primary growth catalyst in this segment is the broader shift toward personalized medicine and value-based reimbursement models, which reward effective dose titration and reduction of hospitalizations. Telehealth expansion and remote patient management platforms are also encouraging physicians to adopt dried blood spot sampling as a pragmatic way to gain pharmacokinetic data without requiring patients to travel. As more drugs receive label support or guidance documents referencing blood spot-based monitoring, payers and providers are increasingly willing to integrate these workflows into routine care, boosting market penetration.
-
Genetic and genomic testing:
Genetic and genomic testing using dried blood spots focuses on DNA- and, in some cases, RNA-based analyses for inherited disorders, carrier screening, and pharmacogenomic profiling. The business objective is to provide accessible, stable samples that can be shipped to specialized sequencing or genotyping laboratories from virtually any collection site. Dried blood spot cards allow large population cohorts, remote clinics, and even direct-to-consumer services to collect genetic material without requiring phlebotomy services or cold-chain logistics.
The unique operational benefit in genetic and genomic testing is the long-term stability and small volume requirement of genomic DNA captured on cards. Many laboratories can extract sufficient DNA from a few punches to perform multiple assays, including array-based genotyping or targeted sequencing, thereby increasing analyte yield per initial sample. When deployed at scale, dried blood spot-based sample collection can reduce upfront logistics and phlebotomy costs significantly, while enabling high-throughput genomic workflows that can process thousands of samples per week.
Growth in this application is driven by the rapid expansion of precision medicine initiatives and large-scale genomic projects in both the public and private sectors. As sequencing costs continue to decline and pharmacogenomic guidelines become more widely adopted in clinical practice, demand for practical collection methods that support broad access is intensifying. Additionally, the increasing use of retrospective genetic analyses on stored neonatal dried blood spots, where permitted, highlights the strategic value of this matrix for future-ready genomic research and clinical translation.
-
Biobanking and longitudinal cohort studies:
Biobanking and longitudinal cohort studies use dried blood spot cards to build large, time-resolved repositories of specimens that support epidemiological research, biomarker discovery, and policy decision-making. The business objective is to store high volumes of samples over many years at manageable cost while preserving analytes of interest for future analytical techniques that may not yet be fully defined. Dried blood spots enable cohorts to collect follow-up samples on a recurring basis without imposing heavy burdens on participants or research budgets.
The operational advantage of dried blood spot-based biobanking lies in the compact storage footprint and reduced reliance on ultra-low temperature freezers compared with traditional serum or plasma biobanks. Research facilities can store millions of cards in controlled ambient or modestly cooled environments, lowering energy consumption and infrastructure costs by a substantial margin. At the same time, the ability to derive multiple assays from archived cards, including hormone levels, certain metabolites, and genetic markers, increases the scientific yield per stored sample and enhances the return on investment for large-scale cohort studies.
Current growth in this application is catalyzed by the expansion of national and regional biobank initiatives and by the increased emphasis on understanding disease trajectories over decades. Funding agencies and research consortia are prioritizing cost-efficient, scalable sample architectures, and dried blood spots are increasingly written into study designs as a standard matrix. As new analytical technologies, such as high-sensitivity mass spectrometry and advanced immunoassays, continue to improve their performance with dried blood spot samples, the strategic relevance of existing and planned card-based biobanks is expected to increase.
-
Public health surveillance and epidemiology:
Public health surveillance and epidemiology applications use dried blood spot cards to monitor disease prevalence, population immunity, and exposure to environmental or nutritional risk factors. The core business objective is to generate statistically robust, geographically distributed data at a feasible cost, enabling evidence-based policy decisions and resource allocation. Dried blood spot campaigns allow ministries of health and international agencies to collect specimens from large numbers of individuals across remote regions in a relatively short timeframe.
Operationally, dried blood spots enable high-throughput serosurveys and biomonitoring programs with minimal infrastructure, as cards can be dried and transported at ambient temperature to central laboratories. Population-based surveillance projects often process tens of thousands of samples over a field season, with dried blood spot workflows supporting rapid sample preparation and batched testing on immunoassay or molecular platforms. This approach can compress data collection timelines by weeks compared with conventional venous sampling, accelerating policy responses during outbreaks or vaccine campaign planning.
The primary catalyst for growth in this application is the increasing frequency of emerging infectious disease threats and the global drive to track progress toward elimination targets. International commitments to monitor vaccine coverage, antimicrobial resistance, and environmental exposures are pushing public health agencies toward scalable sampling methodologies. As more surveillance protocols formally incorporate dried blood spots and as laboratory networks standardize on validated assays for this matrix, demand is expected to grow in tandem with expanding global health monitoring efforts.
-
Pharmacokinetic and toxicology studies:
Pharmacokinetic and toxicology studies leverage dried blood spot cards to collect serial samples for drug development, bioequivalence assessment, and safety evaluations. The business objective is to gather robust time-concentration data with minimal patient or animal burden and lower operational costs, especially in multi-site and global clinical trials. By using dried blood spots, sponsors can simplify logistics, reduce on-site processing requirements, and centralize analytical testing.
The operational outcome that differentiates dried blood spot sampling in pharmacokinetic and toxicology work is the ability to collect many time points using small blood volumes, which is particularly important in pediatric studies and preclinical models. Studies often show that using dried blood spots can reduce the total blood volume drawn per subject by more than 50 percent compared with traditional plasma sampling, while still supporting high-quality LC-MS/MS analyses. In addition, consolidation of analytical testing at a single central laboratory can improve data consistency and reduce variability between sites, shortening development timelines and lowering overall trial costs.
Growth in this application is driven by regulatory acceptance of alternative matrices for pharmacokinetic evaluation and by industry pressure to make clinical trials more patient-centric and efficient. The expansion of global, multi-country studies increases the logistical advantages of ambient-temperature shipping, making dried blood spots attractive for both early-phase and late-phase programs. As more contract research organizations build dedicated expertise and validated methods for dried blood spot pharmacokinetics, pharmaceutical and biotechnology sponsors are likely to expand their use of this approach across portfolios.
-
Home-based and decentralized sample collection:
Home-based and decentralized sample collection represents one of the fastest-evolving applications, using dried blood spot cards to enable patients to self-collect samples outside traditional healthcare facilities. The business objective is to extend diagnostic and monitoring services into the home, improving convenience, adherence, and access, especially for chronic disease management and remote clinical trial participation. Dried blood spots are well suited for postal or courier return, making them a preferred matrix for many mail-in testing services and virtual care models.
The operational advantages in this application include significant reductions in in-person visit requirements, faster enrollment and data capture in decentralized trials, and broader geographic reach for diagnostic providers. Programs that deploy structured home sampling kits with dried blood spot cards frequently report high completion rates, with some remote monitoring initiatives achieving more than 70 percent of participants returning usable specimens on schedule. Health systems benefit from reduced clinic traffic and more flexible staffing, while laboratories can scale processing capacity to handle fluctuating volumes of mailed-in cards using standardized workflows.
The primary growth catalyst is the rapid expansion of telehealth and digital health ecosystems accelerated by both patient expectations and payer interest in cost-efficient care delivery. Regulatory openness to remote testing and decentralized trial designs has further legitimized dried blood spot-driven workflows, encouraging broader adoption among providers, payers, and life science sponsors. As the Global Dried Blood Spot Card Market grows from USD 0.43 Billion in 2025 to an estimated USD 0.56 Billion by 2032, home-based and decentralized sample collection is expected to be one of the key demand engines, channeling incremental volume into both clinical and research laboratories worldwide.
Key Applications Covered
Newborn screening
Infectious disease testing
Therapeutic drug monitoring
Genetic and genomic testing
Biobanking and longitudinal cohort studies
Public health surveillance and epidemiology
Pharmacokinetic and toxicology studies
Home-based and decentralized sample collection
Mergers and Acquisitions
The dried blood spot card market has seen a steady but selective wave of mergers and acquisitions as diagnostics companies reposition around decentralized testing and longitudinal sample collection. Deal flow has accelerated alongside the global market’s expansion toward an estimated USD 0.43 Billion by 2025, with buyers targeting specialized chemistries, automation workflows, and regulatory-cleared product portfolios. Consolidation is driven less by scale alone and more by the need to integrate DBS sampling into broader clinical trial, newborn screening, and real-world evidence platforms.
Major M&A Transactions
BioRad Diagnostics – MicroCard Systems
Expansion of neonatal screening portfolio and DBS manufacturing capacity across regulated markets.
PerkinElmer Health Sciences – NordicSpot Technologies
Acquisition of advanced microfluidic DBS cards enabling lower sample volumes and faster elution workflows.
QIAGEN – CardioSample Labs
Integration of DBS-based cardiovascular biomarker panels into existing molecular diagnostics assay ecosystem.
Roche Diagnostics – HematoCard Solutions
Strengthening hematology-focused DBS testing solutions for remote patient monitoring and chronic disease management.
Sarstedt – MedSpot Biodesign
Enhancing specimen collection device portfolio with customizable DBS cards for pharma-sponsored trials.
Danaher Diagnostics – TraceDry Labs
Securing proprietary stabilizing chemistries that extend DBS sample integrity for global shipment.
Shimadzu Healthcare – AeroBio Card Systems
Linking DBS cards with LC-MS workflows to streamline quantitative therapeutic drug monitoring.
Abbott Diagnostics – GlobalDry CardTech
Broadening decentralized infectious disease testing solutions using DBS samples in low-resource settings.
Recent transactions are gradually increasing market concentration as diversified diagnostics conglomerates consolidate niche DBS innovators. While the overall market remains fragmented, leading acquirers are assembling end-to-end offerings that include collection cards, pre-analytical automation, and assay kits. This bundling strategy raises switching costs for hospitals, reference laboratories, and contract research organizations, thereby strengthening negotiating leverage for the largest platforms.
Valuation multiples in DBS card deals tend to price in both consumable revenue and high-margin assay pull-through. Targets with established pharmaceutical partnerships or inclusion in newborn screening programs often command acquisition premiums, since reimbursement and volume visibility lower integration risk. Given the market’s forecast compound annual growth rate of 3.80 percent through 2032, acquirers appear willing to pay forward-looking EBITDA multiples in line with broader specialized diagnostics, particularly when intellectual property relates to improved analyte stability or multiplex assay compatibility.
Mergers are also reshaping strategic positioning by enabling cross-selling of DBS solutions into existing install bases of analyzers and clinical decision platforms. Buyers increasingly prioritize assets that can rapidly scale across global distribution networks without major revalidation, such as cards already cleared in multiple jurisdictions. This favors targets with strong quality systems, ISO certifications, and data supporting use in high-volume surveillance programs, where reliable card performance directly underpins population-scale testing economics.
Regionally, most deal activity clusters in North America and Europe, where regulatory pathways for in vitro diagnostics and established biobanks create attractive environments for DBS commercialization. However, several buyers explicitly pursue acquisitions with distribution strength in Asia-Pacific and Latin America to capture growing demand for remote sampling in rural and emerging healthcare systems. These cross-regional strategies seek to harmonize card specifications with variable cold-chain and logistics constraints.
On the technology front, acquisitions focus on cards incorporating integrated pre-analytical features, such as volumetric sampling, analyte-stabilizing chemistries, and barcoded data capture that link to laboratory information systems. Such assets are central to the mergers and acquisitions outlook for Dried Blood Spot Card Market, as buyers emphasize interoperability with LC-MS, PCR, and high-throughput immunoassay platforms. Future transactions are likely to prioritize digital tracking, automation-ready formats, and compatibility with decentralized clinical trial workflows.
Competitive LandscapeRecent Strategic Developments
In January 2023, an expansion initiative saw PerkinElmer (now Revvity) broaden its dried blood spot card manufacturing capacity in North America to support higher newborn screening volumes. This expansion type development improved supply security for public health laboratories and intensified competition on lead times and pricing for high-volume tenders, particularly against European suppliers.
In June 2023, a strategic investment agreement between Qiagen and a digital health start-up integrated dried blood spot collection cards with remote patient monitoring platforms for oncology and metabolic disorders. This strategic investment shifted market dynamics toward connected sampling solutions, encouraging incumbents to add barcode tracking, app integration and logistics partnerships to defend share in remote diagnostic programs.
In September 2024, an acquisition transaction involved Shimadzu acquiring a specialty dried blood spot card producer focused on LC-MS/MS applications. This acquisition expanded Shimadzu’s end-to-end workflow offering, from sampling cards to analytical instruments, reinforcing bundled solution sales and raising barriers for standalone card manufacturers in high-sensitivity therapeutic drug monitoring and toxicology testing segments.
SWOT Analysis
-
Strengths:
The Global Dried Blood Spot Card market benefits from strong adoption in neonatal screening, therapeutic drug monitoring, and infectious disease surveillance because the technology enables low-volume sampling, ambient-temperature transport, and simplified logistics. These cards reduce cold-chain dependency, lower phlebotomy costs and allow decentralized specimen collection in remote and resource-limited settings, which makes them attractive for national screening programs and global health initiatives. Vendors leverage proven chemistries for protein and small-molecule stability, along with standardized punching and elution protocols, which support regulatory acceptance and reproducible assay performance. Established OEM relationships with diagnostic instrument manufacturers and reference laboratories further entrench dried blood spot cards in routine clinical workflows and research pipelines, creating recurring consumables revenue and high switching costs for large laboratory networks.
-
Weaknesses:
The market faces inherent limitations related to hematocrit effects, variable spot homogeneity and restricted sample volume, which can compromise quantitative accuracy for certain analytes compared with venous plasma. Many laboratories must invest in additional validation studies, specialized punching equipment and staff training to manage pre-analytical variability, which increases implementation complexity, especially in smaller clinical labs. Intellectual property around specialized coatings and filter papers can constrain product differentiation, leading to perceived commoditization and price sensitivity in high-volume tenders. Furthermore, reimbursement frameworks in some regions are still optimized for conventional venous draws, slowing broader clinical adoption of dried blood spot testing in chronic disease management and limiting the revenue potential of advanced, higher-margin card formats.
-
Opportunities:
The Global Dried Blood Spot Card market has attractive growth potential in home-based sampling, telehealth-enabled chronic disease management and large-scale real-world evidence studies, as payers and providers seek cost-efficient, patient-friendly collection methods. Integration of dried blood spot cards with digital health platforms, pre-labeled logistics kits and cloud-based tracking systems creates opportunities for subscription-style service models targeting oncology, metabolic disorders and rare disease monitoring. Emerging markets in Asia-Pacific, Latin America and Africa are expanding newborn screening and HIV, hepatitis and malaria surveillance programs, creating new procurement channels for high-throughput card formats. In parallel, pharmaceutical companies are incorporating dried blood spot sampling into decentralized clinical trials and pharmacokinetic studies, which can drive demand for validated, assay-specific cards and strengthen long-term supply agreements with contract research organizations.
-
Threats:
The Dried Blood Spot Card market faces competitive pressure from alternative microsampling technologies such as volumetric absorptive microsampling devices and capillary collection tubes that offer fixed-volume, liquid-stable samples with streamlined automation compatibility. Tighter regulations around biohazard transport, data privacy and diagnostic validation could increase compliance costs and lengthen time-to-market for new card chemistries or integrated collection kits. Large in vitro diagnostics companies may prioritize investments in fully integrated point-of-care analyzers that bypass dried matrix sampling altogether, redirecting capital from dried blood spot-centric workflows. In addition, fluctuations in cellulose and specialty paper supply chains, as well as consolidation among major healthcare distributors, may compress margins for smaller card manufacturers and intensify price-based competition in both public and private procurement contracts.
Future Outlook and Predictions
The global Dried Blood Spot Card market is expected to grow steadily over the next decade, tracking a moderate expansion from an estimated USD 0.43 Billion in 2025 to about USD 0.56 Billion by 2032, reflecting a compound annual growth rate of roughly 3.80 percent. This trajectory signals a stable but not explosive market, where entrenched use in newborn screening and therapeutic drug monitoring continues to anchor baseline demand. Growth will be driven less by volume explosions in traditional applications and more by incremental penetration into remote sampling, decentralized diagnostics and longitudinal patient monitoring programs.
Technology evolution will focus on improving analytical robustness and workflow integration rather than radically transforming the core card format. Manufacturers are expected to advance surface chemistries that mitigate hematocrit effects, enhance analyte recovery and stabilize labile biomarkers such as cytokines and certain small molecules. Over the next five to ten years, more cards will be co-developed with specific LC-MS/MS or immunoassay panels, yielding assay-optimized substrates that are validated as part of end-to-end diagnostic workflows and bundled with software-defined extraction protocols.
Digitalization will significantly reshape how dried blood spot cards are deployed in clinical practice and research. Remote sampling kits are likely to incorporate pre-registered barcodes, QR-coded instructions and app-based user guidance that ties directly into laboratory information systems and patient portals. This integration will support telehealth programs for conditions such as diabetes, lipid disorders and HIV, where periodic finger-prick sampling can replace some in-clinic venous draws. As payers focus on cost containment and adherence, these connected solutions will help position dried blood spot cards as a cornerstone of hybrid care pathways.
Regulatory and reimbursement landscapes will gradually adapt to mainstream remote sampling, influencing market structure and competitive barriers. Over the next decade, more jurisdictions are expected to issue specific guidance on dried matrix validation, stability claims and patient self-collection, which will favor vendors with strong clinical evidence and quality systems. At the same time, expanded reimbursement for home-based specimen collection in high-income markets will encourage health systems to embed dried blood spot protocols into chronic disease management programs, adding predictable recurring volumes for compliant suppliers.
Competitive dynamics will evolve toward ecosystem-based offerings rather than standalone consumable sales. Instrument manufacturers, contract research organizations and logistics providers are expected to form tighter alliances with dried blood spot card producers to deliver integrated solutions for decentralized clinical trials and population health surveillance. This shift will reward companies that can pair robust card technology with training, data management and global distribution capabilities, while smaller commodity-focused players may face margin pressure and the need to specialize in niche applications or regional tenders.
Table of Contents
- Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Dried Blood Spot Card Annual Sales 2017-2028
- 2.1.2 World Current & Future Analysis for Dried Blood Spot Card by Geographic Region, 2017, 2025 & 2032
- 2.1.3 World Current & Future Analysis for Dried Blood Spot Card by Country/Region, 2017,2025 & 2032
- 2.2 Dried Blood Spot Card Segment by Type
- Standard filter paper dried blood spot cards
- Pre-printed and barcoded dried blood spot cards
- Integrated collection device dried blood spot cards
- Multi-spot dried blood spot cards
- Specialty treated dried blood spot cards
- Dried blood spot sample collection kits
- 2.3 Dried Blood Spot Card Sales by Type
- 2.3.1 Global Dried Blood Spot Card Sales Market Share by Type (2017-2025)
- 2.3.2 Global Dried Blood Spot Card Revenue and Market Share by Type (2017-2025)
- 2.3.3 Global Dried Blood Spot Card Sale Price by Type (2017-2025)
- 2.4 Dried Blood Spot Card Segment by Application
- Newborn screening
- Infectious disease testing
- Therapeutic drug monitoring
- Genetic and genomic testing
- Biobanking and longitudinal cohort studies
- Public health surveillance and epidemiology
- Pharmacokinetic and toxicology studies
- Home-based and decentralized sample collection
- 2.5 Dried Blood Spot Card Sales by Application
- 2.5.1 Global Dried Blood Spot Card Sale Market Share by Application (2020-2025)
- 2.5.2 Global Dried Blood Spot Card Revenue and Market Share by Application (2017-2025)
- 2.5.3 Global Dried Blood Spot Card Sale Price by Application (2017-2025)
Frequently Asked Questions
Find answers to common questions about this market research report